Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., is a company focused on the health and wellness industry. The firm's business model involves deploying and licensing its proprietary technologies to external partners within the pharmaceutical, vaccine, and nutraceutical sectors. Its portfolio includes Quicksome, an advanced oral drug formulation and delivery system; Quicksol, a technology designed to improve solubility; and a dose-sparing adjuvant. Currently, the company is also progressing with the development of IM032, a treatment being tested in male beagle dogs to assess the differences between intramuscular and subcutaneous administration routes. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
—
Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., is a company focused on the health and wellness industry. The firm's business model involves deploying and licensing its proprietary technologies to external partners within the pharmaceutical, vaccine, and nutraceutical sectors. Its portfolio includes Quicksome, an advanced oral drug formulation and delivery system; Quicksol, a technology designed to improve solubility; and a dose-sparing adjuvant. Currently, the company is also progressing with the development of IM032, a treatment being tested in male beagle dogs to assess the differences between intramuscular and subcutaneous administration routes. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.
—
Daily adjusted close
Mountain Valley MD Holdings Inc., operating through its subsidiary Mountain Valley MD Inc., is a company focused on the health and wellness industry. The firm's business model involves deploying and licensing its proprietary technologies to external partners within the pharmaceutical, vaccine, and nutraceutical sectors. Its portfolio includes Quicksome, an advanced oral drug formulation and delivery system; Quicksol, a technology designed to improve solubility; and a dose-sparing adjuvant. Currently, the company is also progressing with the development of IM032, a treatment being tested in male beagle dogs to assess the differences between intramuscular and subcutaneous administration routes. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.